Moderna flu vaccine delivers mixed results in trial, shares fall

The vaccine was tested against in a trial of 6,102 adults aged 18 and over across Argentina, Australia, Colombia, Panama and the Philippines during flu season there. (Shutterstock)
Short Url
Updated 17 February 2023
Follow

Moderna flu vaccine delivers mixed results in trial, shares fall

  • The company said its vaccine, called mRNA-1010, generated a stronger immune response for the A/H3N2 and A/H1N1 strains than the marketed vaccine

Moderna Inc. on Thursday said its closely watched experimental messenger RNA-based influenza vaccine generated a strong immune response against A strains of the flu but failed to show it was at least as effective as an approved vaccine versus less prevalent influenza B.
The results dashed investor hopes that the company might plug its COVID franchise decline, sending Moderna’s shares down more than 6 percent in after-hours trading.
Moderna, whose only marketed product is its COVID-19 shot, has high hopes for its flu vaccine and aims to grab large portions of the respiratory syncytial virus (RSV) and seasonal flu markets with new mRNA vaccines.
The company said its vaccine, called mRNA-1010, generated a stronger immune response for the A/H3N2 and A/H1N1 strains than the marketed vaccine it was tested against in a trial of 6,102 adults aged 18 and over across Argentina, Australia, Colombia, Panama and the Philippines during flu season there.
It failed to meet its goal of non-inferiority compared to the conventional vaccine for the B/Victoria and B/Yamagata-lineage strains, the drugmaker said.
Cowen analyst Tyler Van Buren said investors had hoped Moderna would replace its COVID revenue with RSV and flu vaccine income, especially after it delivered positive RSV vaccine efficacy results in January.
“But to fill that big COVID decline, you need RSV and flu. The efficacy results could tell a different story when they come out, but there was no doubt that the most recent vaccine data was a mixed bag,” he said.
He said physicians and patients might be put off by Moderna’s flu vaccine’s results for Influenza B and the high rate of side effects.
The US company said it has already updated mRNA-1010 in a way it believes will improve immune responses against Influenza B and will test those changes.
“We have always said our goal is to produce a flu vaccine, and then to iterate it, and to fine tune it over time to really make it exceptional,” Chief Medical Officer Paul Burton said in an interview.
Dr. David Boulware, an infectious disease specialist at the University of Minnesota Medical School, said he was not overly concerned about the immune response versus Influenza B.
Boulware said the immune response against the A strains demonstrated that the vaccine probably worked and Moderna’s tweaks to the vaccine are likely to improve the response against the B strains.
“I consider it pretty positive,” he said.
Seventy percent of those who received Moderna’s shot reported mostly mild adverse reactions compared to 48 percent for the conventional flu vaccine. Pain and swelling at the injection site as well as headaches and fatigue were among the most commonly reported side effects.
The company also has an ongoing late-stage efficacy study on the mRNA-1010 flu vaccine, which could have data within weeks.
If that trial reads out soon, Burton said he hopes to have the data prepared and sent to regulators in the first half of this year, which could allow them to review it as soon as late 2023 or early 2024.
The flu, an infection of the nose, throat and lungs, kills 290,000 to 650,000 people worldwide annually. 


Trump administration reaches a trade deal to lower Taiwan’s tariff barriers

Updated 3 sec ago
Follow

Trump administration reaches a trade deal to lower Taiwan’s tariff barriers

  • The gap reached nearly $127 billion in the first 11 months of 2025. US officials attended the signing through the American Institute in Taiwan
  • The deal comes ahead of President Donald Trump’s planned visit to China in April and suggests a deepening economic relationship between the US and Taiwan
WASHINGTON: The Trump administration reached a trade deal with Taiwan on Thursday, with Taiwan agreeing to remove or reduce 99 percent of its tariff barriers, the office of the US Trade Representative said.
The agreement comes as the US remains reliant on Taiwan for its production of computer chips, the exporting of which contributed to a trade imbalance of nearly $127 billion during the first 11 months of 2025, according to the Census Bureau.
Most of Taiwan’s exports to the US will be taxed at a 15 percent rate, the USTR’s office said. The 15 percent rate is the same as that levied on other US trading partners in the Asia-Pacific region, such as Japan and South Korea.
Trade Representative Jamieson Greer and Commerce Secretary Howard Lutnick attended the signing of the reciprocal agreement, which occurred under the auspices of the American Institute in Taiwan and the Taipei Economic and Cultural Representative Office in the United States. Taiwan’s Vice Premier Li-chiun Cheng and its government minister Jen-ni Yang also attended the signing.
“President Trump’s leadership in the Asia-Pacific region continues to generate prosperous trade ties for the United States with important partners across Asia, while further advancing the economic and national security interests of the American people,” Greer said in a statement.
The Taiwanese government said in a statement that the tariff rate set in the agreement allows its companies to compete on a level field with Japan, South Korea and the European Union. It also said the agreement “eliminated” the disadvantage from a lack of a free trade agreement between Taiwan and the US
The deal comes ahead of President Donald Trump’s planned visit to China in April and suggests a deepening economic relationship between the US and Taiwan.
Taiwan is a self-ruled democracy that China claims as its own territory, to be annexed by force if necessary. Beijing prohibits all countries it has diplomatic relations with — including the US — from having formal ties with Taipei.
Cheng said Taiwan hopes the agreement will make it a strategic partner with the US “so as to jointly consolidate the democratic camp’s leading position in high technology.”
The agreement would make it easier for the US to sell autos, pharmaceutical drugs and food products in Taiwan. But the critical component might be that Taiwanese companies would invest in the production of computer chips in the US, possibly helping to ease the trade imbalance.
In a separate but related deal, Taiwan will make investments of $250 billion in US industries, such as computer chips, artificial intelligence applications and energy. The Taiwanese government says it will provide up to an additional $250 billion in credit guarantees to help smaller businesses invest in the US
The investments helped enable the US to reduce its planned tariffs from as much as 32 percent initially to 15 percent.
Taiwan’s government said it will submit the reciprocal trade deal and investment plans to its legislature for approval.
In Taipei, President Lai Ching-te told reporters that Taiwan had agreed to reduce tariffs on imports from the US but stressed that the rate on 93 items would remain unchanged to protect important agriculture and industrial sectors such as rice farming.
The US side said the deal with Taiwan would help create several “world-class” industrial parks in America in order to help build up domestic manufacturing of advanced technologies such as chips. The Commerce Department in January described it as “a historic trade deal that will drive a massive reshoring of America’s semiconductor sector.”
In return, the US would give preferential treatment to Taiwan regarding the possible tariffs stemming from a Section 232 investigation of the importing of computer chips and semiconductor manufacturing equipment.
TSMC, the chip-making giant, is expected to be the key investor. It has committed to $165 billion in investments in the US, including not only fabrication plants but also a major research and development center that would help build a supply chain to power US artificial intelligence ambitions. Major US tech companies such as Nvidia and AMD rely on TSMC for manufacturing highly advanced chips.
When asked whether investing in the US would endanger Taiwan’s most advanced industries, Lai said: “Whether it’s TSMC or other industries, as long as their R&D centers are in Taiwan, their advanced manufacturing processes are in Taiwan and their largest production volume is in Taiwan, Taiwan can continue to develop steadily.”
Taiwan said the investments will be two-way, with US companies also investing in key Taiwanese industries. Nvidia this week signed a land deal in Taipei to build a headquarters office there.